Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)

Last updated: March 6, 2020
Sponsor: Helsinki University Central Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03855722
RIPTRANS
  • Ages > 18
  • All Genders

Study Summary

Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.

Eligibility Criteria

Inclusion

Donor Inclusion Criteria:

  • Brain-dead organ donor with a plan of harvesting at least one kidney

Exclusion

Donor Exclusion Criteria:

  • Haemodynamically unstable donor

  • Age below 18 years

  • Planned organ recipients are recruited to another prospective trial, which preventsparticipation in this trial. All organ recipients receiving organs (kidney, liver, pancreas-kidney, heart, lungs) from arandomized donor will be recruited providing that the recipient surgery is performed atHelsinki University Hospital, recipient is over 18 years old, and recipient gives writteninformed consent to participate in the trial.

Study Design

Total Participants: 496
Study Start date:
March 12, 2019
Estimated Completion Date:
February 28, 2042

Connect with a study center

  • Helsinki University Hospital

    Helsinki, 00029
    Finland

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.